B Cell Induction in Pediatric Lung Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

January 22, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Lung Transplant
Interventions
BIOLOGICAL

Rituximab (Rituxan®)

2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).

BIOLOGICAL

Placebo

Placebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m\^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/-2 days).

Trial Locations (7)

19104

Children's Hospital of Philadelphia, Philadelphia

43205

Nationwide Children's Hospital, Columbus

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

63110

Washington University, St Louis

77030

Texas Children's Hospital, Houston

94305

Stanford University, Palo Alto

02115

Children's Hospital Boston, Boston

All Listed Sponsors
collaborator

Clinical Trials in Organ Transplantation in Children

OTHER

collaborator

Rho Federal Systems Division, Inc.

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02266888 - B Cell Induction in Pediatric Lung Transplantation | Biotech Hunter | Biotech Hunter